{"entity":{"id":"cd96","kind":"target","name":"CD96","aka":["TACTILE","CD96 molecule","T-cell surface protein tactile"],"tldr":"CD96 sits on T and NK cells and binds CD155, the same molecule TIGIT reads on tumour cells. It is the least tested of that family; one blocking antibody is in phase 2 platform trials in lung cancer.","summary":"CD96 (chromosome 3q13.13) may mediate adhesive interactions of activated T and NK cells in the late phase of the immune response, promoting NK-cell adhesion to targets through PVR (CD155) on the target cell; it is expressed on normal T-cell lines and clones and at very low levels on activated B cells (UniProt P40200). CD155 is the ligand for the co-stimulatory receptor CD226 and the co-inhibitory receptors TIGIT and CD96 (Kučan Brlić et al. 2017). GSK6097608, an anti-CD96 antibody, is being tested in phase 2 platform studies with dostarlimab in non-small-cell lung cancer (NCT05565378, NCT03739710).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:16892","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16892"},{"label":"UniProt P40200","url":"https://www.uniprot.org/uniprotkb/P40200/entry"},{"label":"NCBI Gene 10225","url":"https://www.ncbi.nlm.nih.gov/gene/10225"},{"label":"ClinicalTrials.gov NCT05565378","url":"https://clinicaltrials.gov/study/NCT05565378"}],"tags":["checkpoint-map"],"related":["pvr","tigit","dostarlimab"],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","tigit-blockade"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"CD96","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:16892","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16892","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt P40200","url":"https://www.uniprot.org/uniprotkb/P40200/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:16892","ensembl":"ENSG00000153283","uniprot":"P40200","entrez":"10225","biology":"An immunoglobulin-superfamily receptor of the TIGIT/CD226 axis competing for CD155.","whereFound":["T cells and NK cells (UniProt P40200)","Non-small-cell lung cancer platform trials of GSK6097608"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/cd96/","neighbours":{"target":[{"id":"pvr","kind":"target","name":"CD155 (PVR)","route":"/targets/pvr/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}